COBRE-DIABETES

糖尿病

• 批准号: 10399857
• 负责人: MARIANA GERSCHENSON
• 金额: $ 23.18万
• 依托单位: UNIVERSITY OF HAWAII AT MANOA
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-01 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10399857
• 关键词: Acute; Address; Administrative Supplement; Animals; Bioluminescence; Blood; Blood Volume; Blood gas; Centers of Research Excellence; Chemistry; Clinical; Contract Services; Core Facility; Diabetes Mellitus; Diagnosis; Dose; Electrolytes; Equipment; Evaluation; Fluorescence; Fostering; Funding; Funding Opportunities; Goals; Growth; Hawaii; Hematocrit procedure; Hemoglobin; Individual; Infrastructure; Investigation; Longitudinal Studies; Metabolic; Minority Groups; Modernization; Mus; National Institute of General Medical Sciences; Phase; Population; Prevention; Renal function; Research; Research Personnel; Resources; Roentgen Rays; Services; System; Technology; Testing; Universities; Vision; career development; cost; equipment acquisition; health disparity; imaging system; improved; in vivo; in vivo imaging system; medical schools; operation; rapid test; response

PROJECT SUMMARY/ABSTRACT This application is for a supplement to support a Phase I Center of Biomedical Research Excellence (COBRE) at the University of Hawaii (UH) on Diabetes (1P20GM113134-04) in response to funding opportunity NOT- GM-21-029, “Administrative Supplements for Equipment Purchases for NIGMS-funded Center and Core Facilities”. The COBRE-Diabetes has developed a Resource Core dedicated to supporting career development for young investigators and to foster diabetes-related research in the state, which is acutely needed. It is estimated that a third of the State’s population will be living with diabetes by the year 2050. The COBRE-Diabetes Resource Core goal is to establish a new and easily accessible modern infrastructure to support investigations in the mechanisms, diagnosis, prevention, and/or treatment of diabetes to address health disparities in the minority populations in Hawaii. Our unique aim is to Maintain the growth and enhance the sustainability of Resource Core. With this proposal, we will optimize our core capacity in order to continue capacity improvement that has been successfully initiated in the first Phase of COBRE-Diabetes funding. In order to accomplish this objective, we request funding for the acquisition of two new pieces of equipment. We hope to replace an existing obsolete Xenogen Vivo Vision IVIS Lumina Imaging system with an IVIS Lumina XRMS in vivo imaging system. This is equipment offers cutting edge in vivo fluorescence and bioluminescence technology combined with low dose 2D X-ray allowing for non-invasive and precise metabolic analyses. This will give us an expanded capacity with multiple animals to perform longitudinal studies. The second equipment is an i-STAT clinical blood analyzer that operates with the advanced technology of single- use i-STAT test cartridges offering a wide array of tests on a single platform, including rapid tests for electrolytes, chemistries, blood gases, hematocrit and hemoglobin or the fast evaluation of metabolic status and renal function. This system uses minimal blood volumes, which will not require animal (mouse) sacrifice. Blood analyses are currently done using individual and dedicated kits that is laborious or contracting services outside of the University. There are many projects ongoing in the DRC that can best be performed in Hawaii. Our distance from US mainland requires that we develop a fundamental repertoire of Core services for diabetes research with COBRE resources. The Dean of the Medical School has committed to provide institutional support to cover the cost of operation for three years after the purchase of these equipment.

项目概要/摘要 此申请是对支持第一阶段生物医学卓越研究中心 (COBRE) 的补充 夏威夷大学 (UH) 糖尿病 (1P20GM113134-04) 响应资助机会 NOT- GM-21-029，“NIGMS 资助的中心和核心设备采购行政补充” COBRE-糖尿病开发了一个资源核心，致力于支持职业发展 为年轻的研究人员提供帮助，并促进该州迫切需要的糖尿病相关研究。这是 预计到 2050 年，该州三分之一的人口将患有糖尿病。 COBRE-糖尿病资源核心目标是建立一个新的且易于访问的现代化基础设施，以 支持糖尿病机制、诊断、预防和/或治疗方面的研究，以解决 夏威夷少数民族人口的健康差异。我们的独特目标是保持增长和 增强资源核心的可持续性。通过这个建议，我们将优化我们的核心能力，以便 继续在 COBRE-糖尿病第一阶段成功启动的能力改进 资金。为了实现这一目标，我们请求资金购买两个新的 设备。我们希望将现有过时的 Xenogen Vivo Vision IVIS Lumina 成像系统替换为 IVIS Lumina XRMS 体内成像系统。该设备提供尖端的体内荧光和 生物发光技术与低剂量 2D X 射线相结合，可实现无创且精确的代谢 分析。这将使我们能够扩大对多种动物进行纵向研究的能力。这 第二台设备是i-STAT临床血液分析仪，采用单通道先进技术运行。 使用 i-STAT 测试盒在单一平台上提供广泛的测试，包括快速测试 电解质、化学成分、血气、血细胞比容和血红蛋白或代谢状态的快速评估 和肾功能。该系统使用最少的血液量，不需要牺牲动物（小鼠）。 目前，血液分析是使用单独的专用试剂盒进行的，这是费力的或承包服务 大学之外。刚果民主共和国正在进行的许多项目最适合在夏威夷实施。 我们与美国大陆的距离要求我们开发一套基本的核心服务 利用 COBRE 资源进行糖尿病研究。医学院院长承诺提供 机构支持，以支付购买这些设备后三年的运营成本。

项目成果

The Role of Ferroptosis in Adverse Left Ventricular Remodeling Following Acute Myocardial Infarction.

• DOI: 10.3390/cells11091399
• 发表时间: 2022-04-20
• 期刊: CELLS
• 影响因子: 6
• 作者: Komai, Kyoko;Kawasaki, Nicholas K.;Higa, Jason K.;Matsui, Takashi
• 通讯作者: Matsui, Takashi

Bicuspid and unicuspid aortic valves: Different phenotypes of the same disease? Insight from the GenTAC Registry.

二叶式和单叶式主动脉瓣：同一疾病的不同表型？

• DOI: 10.1111/chd.12520
• 发表时间: 2017
• 期刊: Congenital heart disease
• 影响因子: 0.3
• 作者: Krepp,JosephM;Roman,MaryJ;Devereux,RichardB;Bruce,Adrienne;Prakash,SiddharthK;Morris,ShaineA;Milewicz,DiannaM;Holmes,KathrynW;Ravekes,William;Shohet,RalphV;Pyeritz,ReedE;Maslen,CherylL;Kroner,BarbaraL;Eagle,KimA;Pre
• 通讯作者: Pre

Associations of FGF21 and GDF15 with mitochondrial dysfunction in children living with perinatally-acquired HIV: A cross-sectional evaluation of pediatric AIDS clinical trials group 219/219C.

• DOI: 10.1371/journal.pone.0261563
• 发表时间: 2021
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Gojanovich GS;Jacobson DL;Broadwell C;Karalius B;Kirmse B;Geffner ME;Jao J;Van Dyke RB;McFarland EJ;Silio M;Crain M;Gerschenson M;Pediatric HIV/AIDS Cohort Study
• 通讯作者: Pediatric HIV/AIDS Cohort Study

The effects of Tel2 on cardiomyocyte survival.

Tel2 对心肌细胞存活的影响。

• DOI: 10.1016/j.lfs.2019.116665
• 发表时间: 2019
• 期刊: Life sciences
• 影响因子: 6.1
• 作者: Yorichika,Naaiko;Baba,Yuichi;Shimada,BrianaK;Thakore,Manoj;Wong,SharonM;Kobayashi,Motoi;Higa,JasonK;Matsui,Takashi
• 通讯作者: Matsui,Takashi

The ABCC6 Transporter: A New Player in Biomineralization.

• DOI: 10.3390/ijms18091941
• 发表时间: 2017-09-11
• 期刊: International journal of molecular sciences
• 影响因子: 5.6
• 作者: Favre G;Laurain A;Aranyi T;Szeri F;Fulop K;Le Saux O;Duranton C;Kauffenstein G;Martin L;Lefthériotis G
• 通讯作者: Lefthériotis G